Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 8,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 8,000 shares of the company’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $37.55, for a total transaction of $300,400.00. Following the completion of the sale, the director directly owned 10,500 shares of the company’s stock, valued at $394,275. This trade represents a 43.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Pharvaris Stock Performance

NASDAQ:PHVS traded up $0.69 during trading hours on Friday, reaching $38.20. The company’s stock had a trading volume of 838,126 shares, compared to its average volume of 389,200. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of -12.45 and a beta of -2.33. The firm has a 50-day simple moving average of $35.01 and a 200-day simple moving average of $31.34. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities analysts anticipate that Pharvaris N.V. will post -3.1 earnings per share for the current fiscal year.

Analyst Ratings Changes

PHVS has been the topic of a number of analyst reports. Guggenheim lifted their price target on Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Thursday. Rosenblatt Securities set a $60.00 price objective on Pharvaris in a research note on Wednesday. Morgan Stanley lifted their target price on shares of Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a research note on Wednesday. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research report on Wednesday. Finally, Leerink Partners boosted their price objective on shares of Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $59.50.

Institutional Trading of Pharvaris

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in shares of Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after acquiring an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc increased its stake in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter. Amundi raised its holdings in Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after buying an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after buying an additional 7,879 shares in the last quarter.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris reported that once-daily extended-release deucrictibant reduced HAE attack rates by 83% versus placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a p-value below 0.0001, and the company said the data supported all primary and secondary efficacy endpoints. Regulatory applications are planned to begin in the first half of 2027. Pharvaris CHAPTER-3 topline data
• Positive Sentiment: The CHAPTER-3 results, together with earlier positive data for on-demand deucrictibant, strengthen Pharvaris’ potential to offer convenient oral treatments for both prevention and acute treatment of HAE attacks. Analysts believe the oral formulation could help the company gain market share. Pharvaris HAE market-share analysis
• Positive Sentiment: Analyst sentiment strengthened: Leerink Partners initiated or reiterated a Buy with a $65 price target, RBC Capital raised its target to $62 while maintaining a Buy rating, and Citizens JMP lifted its target to $79 with a Market Outperform rating. HC Wainwright also maintained a Buy rating with a $60 target, reinforcing expectations for substantial upside if development and regulatory plans remain on track.
• Neutral Sentiment: Pharvaris remains a clinical-stage biotechnology company with no approved commercial product. Regulatory review, launch execution, competition from existing HAE therapies, and continued operating losses remain key risks.
• Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The sale may create a modest insider-selling overhang, although it does not alter the favorable clinical data.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.